These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28370541)

  • 1. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
    BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
    Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR
    Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
    Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
    Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
    J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
    Vonesh E; Gooch KL; Khangulov V; Schermer CR; Johnston KM; Szabo SM; Rumsfeld JS
    PLoS One; 2018; 13(10):e0205640. PubMed ID: 30325968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Hairston JC
    Low Urin Tract Symptoms; 2021 Oct; 13(4):425-434. PubMed ID: 33987973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Developments in the medical treatment of overactive bladder].
    Alcántara Montero A
    Semergen; 2016; 42(8):557-565. PubMed ID: 26671329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
    Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
    Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.
    Kinjo M; Yamaguchi T; Tambo M; Okegawa T; Fukuhara H
    Urol Int; 2019; 102(3):331-335. PubMed ID: 30799398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.